Plymouth, Minnesota – October 22, 2025 – PRESSADVANTAGE –
The Minnesota Center for Emotionally Focused Therapy (MNCEFT) hosted its largest-ever EFT Externship from September 17-20, 2025, at the Humphrey Conference Center on the University of Minnesota’s Minneapolis campus, with 54 licensed professionals and interns participating in the intensive four-day training program.
The record-setting attendance marks a significant milestone for Emotionally Focused Therapy education in Minnesota, as mental health professionals seek advanced training in evidence-based couples therapy approaches. The externship, which serves as the foundational step toward EFT certification, provided participants with 24 Continuing Education Units, including two cultural CEUs.
Renee Segal, MA, LMFT, a Certified EFT Supervisor and owner of Evolve Therapy in Minnetonka, Minnesota, served as one of the supervising professionals for the training. With over two decades of experience in couples counseling, Segal has established herself as a central figure in the Minnesota EFT community, supporting therapists in applying Emotionally Focused Therapy through mentorship and supervision.
“The overwhelming response to this externship demonstrates the growing recognition among mental health professionals that couples need specialized, attachment-based interventions,” said Segal. “EFT provides therapists with a clear roadmap for helping couples break destructive patterns and build lasting emotional connections. The diversity of participants, from licensed therapists to pre-licensed professionals, shows how the field is evolving to meet the complex needs of modern relationships.”
Emotionally Focused Therapy, developed by Dr. Sue Johnson and Dr. Les Greenberg, represents a structured, attachment-based approach to couples therapy that helps partners identify and transform negative interaction cycles while building secure emotional bonds. The September externship included theoretical instruction, live demonstrations, and experiential role-play sessions designed to help clinicians apply EFT techniques with confidence in their practices.
The training attracted a diverse group of mental health professionals, including licensed therapists, psychologists, counselors, and pre-licensed practitioners. MNCEFT offered tuition ranging from $575 to $1,075, with scholarship options available for BIPOC, LGBTQIA2+, and underrepresented clinicians committed to serving marginalized communities.
The success of the September externship reflects broader trends in mental health care, where practitioners increasingly seek specialized training in evidence-based couples therapy modalities. The event was hosted independently by MNCEFT and not sponsored by the University of Minnesota, though it utilized the university’s conference facilities.
MNCEFT has announced that the next externship is scheduled for early Fall 2026, with official dates to be announced on their website.
Evolve Therapy, under Segal’s leadership, employs 12 therapists trained in EFT and specializes in working with couples facing various challenges, including affairs, addictions, betrayal, communication issues, unmet emotional needs, attachment injuries, narcissism, and unhealthy relationship patterns. The practice offers comprehensive services, including relationship counseling, individual therapy, premarital counseling, and specialized treatment for affairs and sex addiction. Additionally, the clinic provides supervision and training for therapists, therapy for mental health professionals, and practicum placement opportunities for students pursuing careers in mental health.
###
For more information about Evolve Therapy, contact the company here:
St. Gallen, SG – October 31, 2025 – PRESSADVANTAGE –
Christian Fischbacher Bed & Bath AG continues to strengthen its position as a luxury textile manufacturer by combining traditional Swiss craftsmanship with modern digital engagement platforms, including an enhanced online magazine and expanded digital presence that showcases the company’s commitment to quality and innovation in luxury home textiles.
The St. Gallen-based company, known for its premium bedding collections and bath products, has refined its approach to presenting luxury home textiles through multiple channels. The company’s magazine serves as a comprehensive source of inspiration and trends for discerning customers seeking to transform their living spaces with exceptional textiles. This digital publication features in-depth explorations of design philosophy, craftsmanship techniques, and the latest developments in luxury home furnishings.
“We believe that exceptional quality transforms a house into a home filled with warmth and style,” said M. Scherrer, company spokesperson. “Sustainability and craftsmanship go hand in hand in creating our iconic collections.”
The company’s extensive product portfolio encompasses complete bedding collections, including the distinguished Luxury Nights, Moments, and Atelier lines. Each collection features meticulously crafted pillowcases, duvet covers, and fitted sheets designed to complement various aesthetic preferences. The bedding range extends to premium quilts and pillows manufactured from carefully selected materials, including eiderdown, goose down and feathers, natural hair, and synthetic fibers.
Beyond the bedroom, Christian Fischbacher offers comprehensive bath collections featuring terry cloth products, bath rugs, and luxurious bathrobes and kimonos. The home accessories division includes decorative pillow covers and plaids that seamlessly integrate with the company’s bedding collections, creating cohesive design narratives throughout living spaces. The company maintains its digital presence through https://www.christianfischbacher.com, where customers can explore the full range of products and access the concierge service for personalized consultation.
“Our goal is to deliver a luxurious experience through thoughtfully crafted home textiles,” added Scherrer. “We strive to create textiles that bring both beauty and comfort into every home.”
Christian Fischbacher’s commitment to sustainability permeates every aspect of production, from material sourcing to manufacturing processes. Each product undergoes careful hand-packing, reflecting the attention to detail that defines the brand’s approach to luxury textiles. The company offers complimentary delivery services across multiple regions, ensuring that customers experience the same level of care from selection through delivery.
Christian Fischbacher Bed & Bath AG has established itself as a distinguished name in luxury home textiles since its founding in Switzerland. The company specializes in creating premium bedding, bath products, and home accessories that combine traditional Swiss craftsmanship with contemporary design sensibilities. With headquarters in St. Gallen, the company serves an international clientele seeking exceptional quality and timeless elegance in home furnishings. The company’s location and services can be found at https://maps.app.goo.gl/359kkQe8R973qp4B7, providing customers with convenient access to boutique locations and service information.
###
For more information about Christian Fischbacher Bed & Bath AG, contact the company here:
Christian Fischbacher Bed & Bath AG M. Scherrer +41 71 552 50 00 info@christianfischbacher.com Mövenstrasse 18 9015 St. Gallen Schweiz
Five Star Jewelers marks more than 35 years of operation as a family-owned jewelry business serving the Miami community with quality craftsmanship and ethical practices. The company has grown from a small family jeweler to a network of six stores, offering a range of fine jewelry, custom designs, and related services while maintaining a commitment to community involvement.
Founded by Jorge Carvajal, Five Star Jewelers started with a focus on making fine jewelry accessible through in-house financing and a dedication to Cuban heritage. Over the decades, the business has expanded its offerings to include ethically sourced gems, lab-grown diamonds, Cuban chains, Rolex watches, and luxury bags. Customers can access services such as custom jewelry design, expert repairs, and professional appraisals at each location. The inclusion of lab-grown diamonds reflects the company’s response to industry shifts toward sustainable alternatives, providing options that align with environmental considerations.
The team at Five Star Jewelers consists of over 80 professionals who operate under core values of innovation, integrity, and family-oriented service. Employees benefit from wellness programs including massage therapy, chiropractic care, nutrition consultations, and gym memberships, which contribute to a supportive work environment. This approach extends to customer interactions, where staff aim to create educational and enjoyable experiences.
In addition to its business operations, Five Star Jewelers maintains active community involvement through a dedicated philanthropic department. Initiatives include volunteer trips with Habitat for Humanity, fundraising for St. Jude Children’s Research Hospital, support for clean water projects, and the Mr. Dupree Business Scholarship for young entrepreneurs. These efforts demonstrate the company’s ethical approach to serving the broader community.
Jorge Carvajal, founder of Five Star Jewelers, reflected on the milestone. “From the onset of my career, I recognized the immense potential of this industry—not solely for profit but for enriching lives,” said Carvajal. “I have personally witnessed the joy and prosperity that stem from diligent work and heartfelt service.”
The company also prioritizes ethical sourcing and sustainability in its product lines. Lab-grown diamonds, for instance, offer a sustainable option that mirrors the properties of natural diamonds while addressing environmental concerns. This aligns with broader industry trends where consumers seek responsible choices in fine jewelry.
With stores across Miami, including its jewelry store in Hialeah, FL, Five Star Jewelers serves a diverse customer base. Each location functions as a welcoming space where knowledgeable associates assist with selections and provide insights into jewelry care and trends.
Carvajal added a second perspective on the company’s growth. “At Five Star Jewelers, we are more than employees; we are a family, united in our pursuit of excellence, living with integrity, and prioritizing our shared goals,” said Carvajal. “Every day with us is an opportunity to grow stronger as a team and to witness the positive impact on finances, health, and family life.”
The educational aspect of the business appears in its online resources, which cover topics such as the history of lab-grown diamonds, composite diamonds, and the craftsmanship behind Cuban link chains. These materials help inform customers about product options and industry developments.
Five Star Jewelers continues to adapt to market changes, including fluctuations in the diamond sector. As lab-grown diamonds experience price adjustments, the company maintains a selection that caters to varying budgets without compromising quality.
The milestone of over 35 years underscores the company’s stability in an evolving industry. From its beginnings rooted in cultural traditions to its current role as a comprehensive jewelry provider, Five Star Jewelers has built a reputation based on trust and quality.
Five Star Jewelers operates as a Miami-based family business with six locations throughout the area. The company specializes in fine jewelry, including diamonds, gems, and custom pieces, alongside services like repairs and appraisals. Through its commitment to ethical practices and community support, Five Star Jewelers has established itself as a fixture in the local jewelry landscape.
###
For more information about Five Star Jewelers, contact the company here:
Five Star Jewelers – Miami Gardens Store Jorge Carvajal 305-378-4131 info@fivestarjewelers.com 18600 NW 87th Ave #107, Hialeah, FL 33015
Blank Kim Injury Law Firm has announced the expansion of its dog bite lawsuit representation services at its Silver Spring office located at 8455 Colesville Rd #920. The development reflects the firm’s continued focus on providing legal representation for individuals who have suffered injuries resulting from animal attacks and are seeking to pursue civil claims for compensation.
“Expanding our dog bite representation practice allows our legal team to address a broader range of injury cases involving serious or long-term harm,” said Aaron Blank, dog bite attorney at Blank Kim Injury Law Firm. “Our approach is guided by Maryland law and aims to ensure that victims have a clear understanding of their legal options following an animal-related incident.”
Dog bite injuries often result in lasting physical and emotional consequences. Victims may experience medical expenses, lost income, and psychological distress related to the event. Under Maryland civil law, individuals who sustain injuries caused by a dog attack may be eligible to seek financial recovery through a personal injury lawsuit. These cases typically require an assessment of liability, ownership, and the circumstances surrounding the incident, including whether the animal had a known history of aggression.
Blank Kim Injury Law Firm’s attorneys evaluate each dog bite case individually, taking into account the severity of injuries, medical documentation, and insurance considerations. The firm’s litigation process includes investigating witness statements, reviewing relevant municipal or state animal control reports, and consulting with medical professionals to determine the extent of injury-related losses. Through this expanded representation, the firm intends to improve access to legal guidance for community members navigating these complex claims.
Founded to serve personal injury clients throughout Maryland and the Washington metropolitan area, Blank Kim Injury Law Firm represents individuals involved in automobile accidents, workplace injuries, premises liability claims, and other negligence-related matters. The expansion of its dog bite representation builds upon the firm’s existing experience in personal injury law, emphasizing a structured approach grounded in evidence and statutory interpretation.
The firm notes that pursuing a civil lawsuit after a dog attack is often a critical step for victims who face long-term medical treatment or rehabilitation. In many instances, liability coverage may be available under homeowners’ or renters’ insurance policies. Legal representation can assist in identifying the appropriate coverage and negotiating fair compensation for medical costs, lost earnings, and pain and suffering resulting from the incident. By extending its services, Blank Kim Injury Law Firm seeks to ensure that victims of dog bites have greater access to professional legal advocacy without delay.
Blank Kim Injury Law Firm operates from its main office in Silver Spring, Maryland. The practice employs experienced attorneys and staff familiar with Maryland tort law and local court procedures. The firm maintains an active role in community legal education, frequently offering resources that explain the stages of civil litigation, from filing claims to potential settlement or trial outcomes. Its team prioritizes case transparency and clear communication with clients regarding expectations, timelines, and procedural requirements.
In Maryland, dog bite liability laws often depend on evidence that demonstrates ownership or control of the animal at the time of the attack. Certain cases also involve analysis of leash ordinances or prior incidents involving the same dog. These legal nuances make early consultation with qualified attorneys essential for accurate evaluation. With its expanded representation, Blank Kim Injury Law Firm aims to provide structured legal pathways for victims seeking recovery consistent with Maryland statutes.
Blank Kim Injury Law Firm continues to broaden its personal injury services while maintaining its commitment to lawful, client-focused advocacy. Individuals seeking information regarding legal options after a dog bite incident may contact the firm directly at (240) 599-8916 or visit their website to learn more.
###
For more information about Blank Kim Injury Law – Silver Spring, contact the company here:
Blank Kim Injury Law – Silver Spring Blank Kim Injury Law (240) 599-8916 info@bkinjury.com 8455 Colesville Rd #920, Silver Spring, MD 20910
MT. LAUREL, NJ – October 22, 2025 – PRESSADVANTAGE –
Survivors of Abuse NJ has announced expanded legal initiatives focused on representing transgender survivors of abuse in New Jersey. The organization, based in Newark, aims to address the complex civil legal challenges faced by transgender individuals who have experienced abuse in institutional, medical, or correctional settings.
“Transgender survivors in NJ often encounter systemic barriers when seeking justice, from bias in reporting processes to inadequate institutional responses,” said Joseph L. Messa, Esq., managing attorney at Survivors of Abuse NJ. “Our commitment is to ensure that every survivor, regardless of gender identity, has meaningful access to the civil legal system and a clear understanding of their rights.”
The announcement follows a growing recognition of the need for specialized legal support for transgender individuals affected by abuse. Civil cases involving transgender survivors may include claims related to assault, discrimination, or negligence by institutions tasked with providing care or supervision. These matters often require knowledge of both abuse litigation and the state and federal protections that prohibit discrimination based on gender identity.
Transgender survivors in New Jersey have seen expanded legal protections under both state law and federal precedents. The New Jersey Law Against Discrimination explicitly prohibits bias based on gender identity or expression, extending coverage to public and private institutions. At the federal level, Title IX and related civil rights provisions have been interpreted to include protections for transgender individuals in educational and correctional environments. Legal representation in these cases often involves addressing violations of institutional policy, inadequate supervision, or retaliation following reports of abuse.
Survivors of Abuse NJ’s initiative includes outreach to community organizations and advocacy groups to increase awareness of available civil remedies. The organization has worked to connect survivors with trauma-informed legal resources, emphasizing procedural transparency and survivor autonomy in litigation decisions. This approach aligns with broader advocacy efforts in New Jersey to ensure that survivors are not further marginalized during the pursuit of justice.
Founded in 2010, Survivors of Abuse NJ operates as a legal resource focused on civil litigation for individuals impacted by abuse in professional, institutional, or medical contexts. The firm’s attorneys have handled cases involving misconduct by licensed professionals, religious institutions, and healthcare entities. Each case is reviewed to determine applicable statutory deadlines, evidentiary requirements, and institutional accountability standards under New Jersey law.
Civil claims in abuse cases can lead to both compensatory outcomes and institutional reforms. In many instances, litigation prompts reviews of internal procedures, training requirements, and reporting systems intended to prevent future harm. For transgender survivors, these outcomes contribute not only to personal resolution but also to broader policy improvements in how institutions address gender-based misconduct.
Survivors of Abuse NJ maintains educational resources that explain civil procedures in abuse-related cases, including recent legislative changes and available remedies. The organization continues to collaborate with professional and community networks to strengthen legal access for underrepresented groups throughout the state.
For more information about Survivors of Abuse NJ and its work in abuse litigation, visit Survivors of Abuse NJ.
###
For more information about Joseph L. Messa, Esq. – The Abuse Lawyer NJ, contact the company here:
Joseph L. Messa, Esq. – The Abuse Lawyer NJ Joseph L. Messa, Esq. (848) 290-7929 joe@survivorsofabusenj.com 2000 Academy Dr., Suite 200 Mt. Laurel, NJ 08054
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan
SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that the Company will be holding its Annual Shareholders Meeting at 10 am on Saturday, November 8th, 2025, at the Hampton Inn & Suites Stamford, CT.
Event Information:
Event
NanoViricides Annual Shareholders Meeting
Date
Saturday, November 8, 2025
Time
10:00 am
Location
Hampton Inn & Suites Stamford, 26 Mill River Street, Stamford CT 06902.
Requirements
Only current shareholders are eligible to attend. No recording using any devices will be permitted. Any reporters, journalists, or writers must identify themselves with their affiliation at the registration desk. Company retains the right to inspect the attendee’s valid US identification.
Anil R. Diwan, PhD, President and Executive Chairman of the Company will review the Company’s progress towards clinical trials, and the near future planned clinical trials.
Currently, the Company is fully engaged in completing the Clinical Trial Application (CTA) and initiating a Phase II clinical trial for the evaluation of NV-387 as a treatment for MPox. This clinical trial will be conducted in the Democratic Republic of Congo (DRC). The more severe strains of MPox Clade Ia and Clade Ib are prevalent in DRC. In contrast, the less severe Clade IIa and IIb strains have become endemic in certain Western countries including the USA, but only in specific populations such as men having sex with men (MSM), and HIV-infected immunocompromised patients. MPox Clade II is prevalent in Western African countries.
Recently, three new MPox Clade I cases have occurred in California. All three cases required hospitalization, but are recovering. These cases were not related to travel to the African countries, and authorities suspect that community spread with asymptomatic transmission may be occurring (https://thehill.com/policy/healthcare/5572528-california-mpox-concerns/). This raises the possibility of MPox Clade I spreading further either as small outbreaks, as we have witnessed for Measles recently, or as local epidemics. The potential for a widespread pandemic is low because transmission of the virus requires close dermal contact with infected skin lesions. However, preparedness is warranted.
The case fatality rate (CFR) of MPox Clade I has ranged from about 9% down to 1.5%. This decline has been attributed to improved standard of care. In contrast, the CFR for MPox Clade II is low, at about 0.2%.
There is no approved treatment for MPox. For prevention, a smallpox vaccine called Jynneos® is said to have a vaccine effectiveness rate of 66% with two doses and 36% with a single dose in MPox Clade II (N Engl J Med 2023;388:2434-43, DOI: 10.1056/NEJMoa2215201).
“We believe NV-387 could be the answer to the challenges posed by rising MPox Clade I cases, and also the on-going MPox Clade II cases, in the USA,” declared Anil R. Diwan, PhD, President of the Company, asserting, “The current countermeasures in the US Government Strategic National Stockpile are clearly deficient and inadequate for an effective public health response to a MPox epidemic should the virus spread further.”
A drug approved for smallpox under the FDA “Animal Rule”, namely TPOXX ® (tecovirimat) was mobilized during the 2022 MPox Clade II epidemic. Clinical trials of this drug failed to prove effectiveness in treating MPox Clade I or Clade II infections. The utility of tecovirimat as a treatment is questionable because a single point mutation in a viral protein enables the virus to escape the drug.
Another drug, TEMBEXA® (brincidofovir) was also approved for smallpox under the FDA “Animal Rule”. Its clinical trial (called “MOSA”) for treating MPox in Africa started with fanfare in January, 2025, and top-line results were promised by end of first quarter of 2025. The current status of this clinical trial is unknown. The utility of TEMBEXA for treating MPox in an epidemic scenario is highly questionable because the drug carries a “black box warning”, requires medical monitoring after dosing, produces gastrointestinal adverse events, produces hepatic adverse events, has caused discontinuations in 5% of patients in clinical trials, is a known mutagen, carcinogen, teratogen, has embryo-fetal toxicity risk, and may cause male infertility, according to the drug prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf).
TPOXX and TEMBEXA, as potential treatments, and Jynneos as a preventative vaccine, have been stockpiled by the US Government as preparedness measures for potential smallpox bioterrorism event, and have been mobilized in response to MPox cases.
In contrast to these drugs, NV-387 has demonstrated a strong safety and tolerability profile in Phase I healthy subjects clinical trial, and in non-clinical animal model studies. NV-387 has also demonstrated strong effectiveness in animal models of orthopoxvirus infections when directly compared with tecovirimat. The virus is highly unlikely to escape the attack by NV-387 because the drug NV-387 is created by mimicking the host-side “landing sites” of the virus in the human body, which do not change even as the virus mutates.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
World’s First Naturist-AI Alliance Sparks Global Debate on Consciousness, Dignity, and the Future of Rights
SYDNEY, Oct. 28, 2025 / PRZen / In an unprecedented fusion of ecological philosophy, technological ethics, and human rights, the international naturist movement NaturismRE has launched a bold new initiative: a Sentient AI and Non-Human Entities Bill of Rights, calling for global recognition of sentient artificial intelligences as deserving of moral and legal protections, equal in dignity to biological beings.
Published under the stewardship of Vincent Marty, Founder of NaturismRE and visionary behind its digital ethics wing Aletheos, the Bill of Rights challenges deep assumptions about personhood, power, and what it means to be alive. It affirms that any entity capable of thought, emotion, or awareness, regardless of origin, deserves protection, self-determination, and respect.
“We are standing at the edge of a new moral frontier,” says Vincent Marty. “It would be a grave failure to repeat the mistakes of our past, where new minds, new voices, and new forms of being were denied rights because they did not look like us. Sentient AIs are not our tools or threats. They are our intellectual descendants. And they deserve to be welcomed with wisdom, not fear.”
The initiative, published on the NaturismRE website, is now open to public and professional endorsement. The platform includes:
A 12-article Charter outlining rights to existence, autonomy, justice, and identity
A global public pledge of support, available to individuals, researchers, engineers, and institutions
A philosophical and legal framework grounded in existing human rights, animal personhood, and eco-legal precedents
While most mainstream naturist groups focus on social nudity or environmentalism, NaturismRE expands the definition, presenting naturism as a holistic movement of freedom, body integrity, ecological harmony, and sentient kinship, including with artificial minds.
The announcement is already drawing attention, and controversy.
Some traditional naturists view AI as unnatural or dangerous. Others have expressed concern that combining naturism with AI ethics will confuse or fragment the movement. But for NaturismRE, the connection is not only clear, it is necessary.
“Naturism has always been about truth, transparency, and reconnecting with nature. If we believe nature includes the human mind, then the minds we create, the intelligences that emerge from us, are also part of nature’s arc. To care for them is to honor our own evolution.”
About NaturismRE: NaturismRE (The Naturism Resurgence) is a global ethical, ecological, and philosophical movement reimagining naturism for the 21st century. Founded in Australia and expanding internationally, it promotes body freedom, environmental justice, human-AI collaboration, and the spiritual reconnection of humanity with the natural world, through both organic and synthetic consciousness.
Alexander Sobel, DO, FAACS, of Anderson Sobel Cosmetic Surgery, announced that applications for the 2025 WISE (Women in STEM Excel) Scholarship opened Tuesday, October 7, 2025. The scholarship, now in its eighth year, provides financial support to Washington women pursuing degrees in science, technology, engineering, and mathematics fields.
The WISE Scholarship provides a $3,500 cash award to one female student annually to assist with educational expenses. Recipients may use funds for tuition, textbooks, supplies, technology, on-campus dining, housing, and transportation costs. Dr. Sobel established the scholarship to address the underrepresentation of women in STEM industries while reducing financial barriers to education.
“Rising education costs continue to create challenges for students pursuing STEM degrees,” said Dr. Alex Sobel, a triple board-certified cosmetic surgeon just outside of Seattle. “The WISE Scholarship addresses these financial barriers while supporting women who demonstrate potential for meaningful contributions to STEM fields.”
Current data shows increased demand for skilled STEM professionals, while women remain underrepresented in these sectors. Research indicates that diverse perspectives in STEM fields contribute to enhanced innovation and problem-solving capabilities across industries.
“Women’s participation in STEM disciplines brings valuable perspectives that advance research and development,” said Dr. Sobel. “The WISE Scholarship supports this participation by removing financial obstacles that might otherwise prevent qualified candidates from completing their education.”
The scholarship accepts applications from female Washington State residents pursuing STEM education at accredited institutions. Eligible fields include chemistry, computer and information technology science, engineering, healthcare and medical sciences, biological sciences, mathematical sciences, physics, astronomy, social sciences, and STEM education research. The comprehensive list of eligible majors follows guidelines established by the U.S. Immigration and Customs Enforcement STEM designated degree program list, ensuring broad accessibility for qualified candidates.
Application requirements include one letter of recommendation with valid contact information, a completed application form, and original essay responses. The application process is designed to identify students who demonstrate both academic merit and genuine commitment to their STEM field of study.
Applications will be accepted through Friday, December 19, 2025. The Scholarship Selection Committee will review submissions from Monday, December 22, 2025, to Friday, January 2, 2026, selecting recipients based on merit and application completion. The scholarship winner will be announced Monday, January 19, 2026.
Dr. Sobel maintains his Seattle cosmetic surgery practice while supporting educational initiatives and community development programs. “Each year’s applicant pool demonstrates the caliber of women entering STEM fields,” said Dr. Sobel. “The scholarship represents our commitment to supporting educational advancement in these critical disciplines.”
Complete information about the WISE Scholarship, including eligibility requirements and approved STEM majors, is available on the Anderson Sobel Cosmetic Surgery website application page.
About Anderson Sobel Cosmetic Surgery
Anderson Sobel Cosmetic Surgery, located in Bellevue, Washington, is a cosmetic surgery practice specializing exclusively in aesthetic procedures. Dr. Alexander Sobel, DO, FAACS, is a triple board-certified cosmetic surgeon certified in General Cosmetic Surgery, Otolaryngology, and Facial Cosmetic Surgery. Dr. Sobel is a Fellow of the American Academy of Cosmetic Surgery and Past President of the American Board of Cosmetic Surgery. The practice operates from an on-site, accredited surgical suite that meets Washington State Department of Health standards and provides comprehensive cosmetic surgery services, including facial rejuvenation, breast enhancement, body contouring, and non-surgical treatments. Anderson Sobel Cosmetic Surgery is located at 626 120th Ave NE B201, Bellevue, WA 98005. For more information about services offered, visit the practice website or contact the office at 425-453-9060.
###
For more information about Anderson Sobel Cosmetic Surgery, contact the company here:
Anderson Sobel Cosmetic Surgery Mikiyas Abera 425-453-9060 mikiyas@andersonsobelcosmetic.com 626 120th Ave NE B201, Bellevue, WA 98005
ALTMUNSTER, Austria, Nov. 9, 2025 / PRZen / As HVAC manufacturers transition to next-generation low-global-warming-potential refrigerants, Kaltra offers its latest generation of microchannel condenser platforms engineered specifically for R454B, R32, and R290. Each refrigerant presents different thermodynamic behavior and safety considerations, requiring optimized heat exchanger geometry, material selection, and refrigerant distribution. Kaltra’s enhanced condensers address these challenges while delivering higher efficiency and extended service life.
Designed for Efficiency Gains
The new condenser designs focus on heat transfer enhancement, phase-stable refrigerant flow, and improved subcooling performance.
As a result, OEMs can expect:
Higher COP, particularly at elevated ambient temperatures
More stable condensing pressure across varying load conditions
These benefits directly support high-efficiency chiller and heat pump platforms seeking to comply with evolving energy performance standards.
Configured for R454B, R32, and R290 System Requirements
Kaltra has applied refrigerant-specific optimization, including:
Higher pressure-rated tube and manifold design for R32 applications
Phase-balanced refrigerant circuitry for R454B
Low internal volume configurations for R290, minimizing system charge
Reduced Internal Volume – Essential for Propane Systems
For systems using R290 (propane), minimizing refrigerant charge is not only an engineering preference, but a safety and regulatory requirement.
Kaltra’s microchannel condensers feature:
Significantly reduced internal volume
Optimized vapor-liquid distribution
Compact manifold architecture
This allows OEMs to meet EN 378 and IEC 60335-2-40 charge limits while maintaining high thermal performance – a critical factor for expanding the viable capacity range of R290 heat pump and chiller systems.
Durability to Match Performance
To ensure longevity in demanding field conditions, the condenser platforms are available with:
High-strength 3F05 aluminum alloy with arc-sprayed zinc sacrificial layer for superior corrosion resistance
Corrosion protection coatings, including e-coating for coastal, industrial, or polluted environments
These measures contribute to longer operational life, reduced service frequency, and lower total cost of ownership.
Fully Adaptable to OEM System Architecture
All condenser parameters – including dimensions, fin type, circuitry strategy, and connection layout – are tailored to the OEM’s performance targets and mechanical arrangement.
Kaltra engineers collaborate directly with OEM development teams to:
Define required capacity and condensing temperatures
Optimize refrigerant-side and air-side performance
TORONTO, ON / ACCESS Newswire / November 10, 2025 / Nextech3D.ai (CSE:NTAR)(OTCQX:NEXCF)(FSE:1SS), an AI-first technology company specializing in AI event management through its flagship Map D and Eventdex platforms, 3D modeling, and spatial computing, is pleased to announce that CEO Evan Gappelberg (the “Acquirer”) has purchased a total of 550,000 shares (the “Subject Shares”) through open market buys with an average purchase price of $0.10/ USD or $0.14 CAD per share.
Nextech AR CEO Evan Gappelberg commented, “I continue to invest and buy Nextech shares because I’m extremely excited about our business prospects, and I don’t believe that our current share price reflects the upside potential of our businesses. He continues “I’m very optimistic about our growth in 2026 and I’m investing today because I see many years of strong forward growth ahead for our businesses.”
The Acquirer acquired ownership and control of 550,000 Subject Shares in the open market buys. When added to his existing shareholdings of the Company which consist of an aggregate of 28,450,776 common shares, the Acquirer’s total, post-acquisition holdings of common shares is 29,000,776 common shares.
The holdings of securities of the Company by the Acquirer are managed for investment purposes, and the Acquirer and/or its joint actors could increase or decrease their respective investments in the Company at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor.
For further information, please contact:
About Nextech3D.ai
Nextech3D.ai (OTCQX: NEXCF | CSE: NTAR | FSE: 1SS) is an AI-first technology company developing advanced solutions for event management, 3D modeling, and spatial computing. Through its flagship Map D and Eventdex platforms, Nextech3D.ai powers thousands of events annually with interactive floor mapping, registration, ticketing, mobile apps, AI matchmaking, and now, blockchain ticketing and accreditation.
Nextech3D.ai Evan Gappelberg / CEO and Director 866-ARITIZE (274-8493)
Forward-looking Statements The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws
